Rajnandini Bhadra is from SRMIST India. Her research goal are directed towards the development and utilisation of plants and microbes in the developing a sustainable planet. My current research articles includesusage of microbes in biodegradation of plastics in the marine environment, phytoproteins in suppression of breast cancer metastasis, green synthesis of nanoparticles.

Niaj Morshed is from khwaja yunus ali university at Bangladesh. His research interest is phytochemical and pharmacological screening of leaves of barleria lupulina and adme/t properties analysis of its isolated compounds.

Wu Mingshu who works as quality & safety and patient experience director in a private cancer hospital in Guangzhou China. She has rich experience in greenfield hospital setting ups and quality & safety management. She successful led JCI & TUV accreditation for a high-end private women & children’s hospital in 2017

Madhu Gupta is working as an Associate Professor in Delhi Pharmaceutical Science and Research University, New Delhi. She has research experience pertaining to drug delivery to nanoformulations for magical molecule delivery, bioligands for targeting of bioactives and drug moiety, biopolymers, cancer nanomedicine as well as topical delivery that is carried out at Department of Pharmaceutical Sciences, Dr. H.S. Gour Central University, Sagar. She has over 80 research publications to her credit published in journals of high scientific impact and contributed 30 chapters in various renowned books and to several international and national books. She has the recipient of Research Excellence of the Year 2020, Youth Education Icon of the Year 2018, Young Scientist Award, Best Administrative Service Award, IDMA-G.P. Nair award and Prof. C.S. Chauhan award. She has also filed the PCT patent for effective wound healing therapy. She has the awardees of various national and International conference in the form of best oral and poster presentation award. as APTI and other. She has also organized so many National and international Conferences

Amrik has a PhD in biochemistry/protein engineering from the University of Leicester after which he spent 6 years at the Institute of Biotechnology, Cambridge University investigating bacterial pathways involved with the metabolism of illicit drugs and high explosives. In 2002, Amrik joined Domantis Ltd developing domain antibodies (dAbs). Following the acquisition of Domantis by GSK, he became Head of Topical Delivery (Biopharm Discovery Unit), supporting the development of biotherapeutics for delivery into the eye, skin and lung. In 2013 he joined Avacta as Chief Scientific Officer to develop the Affimer platform for therapeutic use.